Crossmark

Risk of metformin use in patients with T2DM and advanced CKD

Crossref DOI link: https://doi.org/10.1038/nrendo.2015.132

Published Online: 2015-08-18

Published Print: 2015-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Schernthaner, Guntram

Schernthaner-Reiter, Marie Helene
License Information

Text and Data Mining valid from 2015-08-18
More Information

Article History

First Online: 18 August 2015

Competing interests

: G.S. has served on advisory boards for Astra Zeneca, Boehringer Ingelheim, Bristol–Myers Squibb, Eli Lilly, Johnston & Johnston and Takeda, and has served as a speaker for Astra Zeneca, Boehringer Ingelheim, Bristol–Myers Squibb, Eli Lilly, Merck, Novo Nordisk, Sanofi and Takeda. M.H.S.-R. declares no competing interests.